Literature DB >> 25634222

Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease.

Kathleen Lee-Sarwar1, Christina Johns2, Tanya M Laidlaw3, Katherine N Cahill4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25634222      PMCID： PMC4426242          DOI： 10.1016/j.jaip.2015.01.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.

Authors:  Andrew A White; Donald D Stevenson; Ronald A Simon
Journal:  Ann Allergy Asthma Immunol       Date:  2005-10       Impact factor: 6.347

2.  Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease.

Authors:  Jennifer Y Lee; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2006-11-13       Impact factor: 10.793

3.  Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.

Authors:  Monika Świerczyńska-Krępa; Marek Sanak; Grażyna Bochenek; Paweł Stręk; Adam Ćmiel; Anna Gielicz; Hanna Plutecka; Andrzej Szczeklik; Ewa Niżankowska-Mogilnicka
Journal:  J Allergy Clin Immunol       Date:  2014-04-24       Impact factor: 10.793

4.  Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease.

Authors:  S Comert; E Celebioglu; T Yucel; T Erdogan; G Karakaya; M Onerci; A F Kalyoncu
Journal:  Allergy       Date:  2013-10-14       Impact factor: 13.146

5.  The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease.

Authors:  Andrew A White; John V Bosso; Donald D Stevenson
Journal:  Allergy Asthma Proc       Date:  2013 Jul-Aug       Impact factor: 2.587

6.  Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.

Authors:  A Rozsasi; D Polzehl; T Deutschle; E Smith; K Wiesmiller; H Riechelmann; T Keck
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

7.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

Review 8.  Aspirin intolerance and the cyclooxygenase-leukotriene pathways.

Authors:  Andrew Szczeklik; Marek Sanak; Ewa Nizankowska-Mogilnicka; Bogumila Kiełbasa
Journal:  Curr Opin Pulm Med       Date:  2004-01       Impact factor: 3.155

9.  Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.

Authors:  K Fruth; B Pogorzelski; I Schmidtmann; J Springer; N Fennan; N Fraessdorf; A Boessert; D Schaefer; J Gosepath; W J Mann
Journal:  Allergy       Date:  2013-03-07       Impact factor: 13.146
  9 in total
  9 in total

Review 1.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 2.  Update on Aspirin-Exacerbated Respiratory Disease.

Authors:  Katharine M Woessner
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.806

3.  Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.

Authors:  Elina Jerschow; Matthew L Edin; Yuling Chi; Beth Hurst; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin P Fried; Weiguo Han; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Victor Schuster; Simon Spivack; David Rosenstreich; Darryl C Zeldin
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-21

4.  Automated identification of an aspirin-exacerbated respiratory disease cohort.

Authors:  Katherine N Cahill; Christina B Johns; Jing Cui; Paige Wickner; David W Bates; Tanya M Laidlaw; Patrick E Beeler
Journal:  J Allergy Clin Immunol       Date:  2016-07-25       Impact factor: 10.793

Review 5.  Immediate Drug Hypersensitivity.

Authors:  Paige G Wickner; David Hong
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

Review 6.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

Review 7.  Aspirin-exacerbated respiratory disease: A review.

Authors:  Christine Dominas; Shekhar Gadkaree; Alice Z Maxfield; Stacey T Gray; Regan W Bergmark
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-05-01

8.  The importance of timely diagnosis of aspirin-exacerbated respiratory disease for patient health and safety.

Authors:  Kathleen Buchheit; Jillian C Bensko; Erin Lewis; Deborah Gakpo; Tanya M Laidlaw
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-09-08

Review 9.  Managing Chronic Rhinosinusitis with Nasal Polyps in the Elderly: Challenges and Solutions.

Authors:  Tyler Merrill; Alissa Kanaan
Journal:  Clin Interv Aging       Date:  2022-05-02       Impact factor: 3.829
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.